We summarize herein our 14-year experience of conventional treatment outcomes before the era of moleculartargeted therapy and immunotherapy. Specifically, we conducted a retrospective review of our 252 patients with primary cutaneous melanoma (acral lentiginous melanoma [ALM], n = 121; non-acral lentiginous melanoma [non-ALM], n = 131), and compared the prognostic factors between ALM and non-ALM. Melanoma-specific survival and disease-free survival were estimated using the Kaplan-Meier method. Regarding the results, all patients were Japanese (106 male and 146 female), with a mean age of 60.1 years. Among ALM patients, age was elder and primary tumor size was larger than non-ALM. As for tumor thickness, in situ lesions were more frequently observed in ALM. There was no significant difference in the distribution of tumor thickness between the two groups when excluding the in situ lesions. For treatment of the primary melanoma, 248 patients (98.4%) had undergone curative surgical excision and 120 patients with more than 1 mm or ulcerated melanoma had undergone sentinel lymph node biopsy. Patients with systemic metastasis primarily underwent dacarbazine-based chemotherapy. The Kaplan-Meier survival curves revealed no significant difference in melanoma-specific survival and disease-free survival between those with ALM and non-ALM. The results also showed that both ALM and non-ALM, when they initially metastasize, first affect the regional lymph nodes. Incisional biopsy was not an adverse prognostic factor. These results suggest that ALM does not differ in its biological behavior from non-ALM, so we can consider ALM as being equivalent to non-ALM. The initial treatment for ALM and non-ALM can involve the same strategy.
INTRODUCTION
Malignant melanoma is one of the most aggressive malignant tumors and is associated with a high risk of mortality. Its incidence is also increasing worldwide. [1] [2] [3] Melanoma has four histopathological subtypes: (i) superficial spreading melanoma; (ii) nodular melanoma; (iii) lentigo maligna melanoma; and (iv) acral lentiginous melanoma (ALM). ALM was first established by Reed in 1976. 4 It typically occurs on the palms, soles and nail beds. Compared with the other subtypes, ALM is unique in that: (i) it arises on non-sun-exposed areas; and (ii) it commonly occurs in darker skinned populations. There are also significant genetic differences between ALM and the other subtypes, [5] [6] [7] so the biology of ALM is likely to differ from that of non-ALM, leading to differences in the biological behavior of the tumors, such as the pattern of metastatic spread and patient prognosis. We previously reported the efficacy of sentinel lymph node (SLN) biopsy in patients with ALM and the clinicopathological condition that SLN biopsy should be performed. 8 Our previous results well fitted with the current recommendations of the American Joint Committee of Cancer and the National Comprehensive Cancer Network. These recommendations were, however, mainly obtained from studies of melanoma cohorts containing only a small proportion of ALM patients and thus may not necessarily be applicable to ALM patients. Our data suggested that SLN biopsy is useful to predict the outcomes of ALM patients and that patients with thick (>1 mm) or ulcerated ALM should be considered for SLN biopsy; in contrast, SLN biopsy may be of limited importance for patients with thin (≤1 mm) or non-ulcerated ALM. Taken together, we provided some evidence that we can equivalently deal with SLN of ALM as that of non-ALM. 6 Although ALM has a significantly different genetic background from non-ALM, including infrequent BRAF mutations and frequent KIT mutations, 5-7 our experiences in daily practise have not suggested that there is a major difference in biological behavior between ALM and non-ALM. Does ALM thus require a different management strategy from non-ALM in a clinical context? The current study was conducted to answer the question. In this study, we show that ALM does not differ from non-ALM in terms of prognostic factors, patient outcome and patterns of metastasis, which suggests that we can treat ALM in a similar way to non-ALM. The results of this study constitute a summary of the effects of our conventional treatments before the era of molecular-targeted therapy and immunotherapy, and thus can be used as a historical control.
METHODS
This study involves a retrospective review of our patients and was conducted in accordance with the principles embodied in the Declaration of Helsinki, and approved by the ethics committee of Kyushu University (no. 26-1). 
Patients
In our records, we found 294 patients with primary malignant melanoma at any anatomical site and identified a total of 252 patients with primary cutaneous melanoma (ALM, n = 121; non-ALM, n = 131) at the Department of Dermatology of Kyushu University Hospital, Japan, between 2001 and 2014. All lesions included in this study were on the skin, and mucosal melanomas and melanomas with unknown origin were excluded. Clinical and demographic data were retrieved from the patient files.
Follow-up data were available for all of the 252 patients with melanoma. At the last follow up, 89 of the 121 patients with ALM were alive, 80 of whom had not experienced metastasis, 24 patients had died of melanoma and eight had died of other causes. Regarding patients with non-ALM, 104 of the 131 patients were alive, 95 of whom had not experienced metastasis, 24 patients had died of melanoma and three had died of other causes. Melanoma-specific survival and disease-free survival were calculated from the date of the first histopathological examination to the date of death due to melanoma, or the date of local recurrence or distal metastasis. Data on patients without death or metastasis were censored on the date of the last follow up before 31 August 2014. Among all of the melanoma patients, six underwent molecular-targeted therapy or immunotherapy (vemurafenib, ipilimumab and nivolumab) and the survival data on these patients were censored at the time of the initiation of the molecular-targeted therapy to remove its potential influence. The median follow-up periods for ALM patients were 35.5 months (mean, 49.4) for melanoma-specific survival and 28.5 months (mean, 43.9) for disease-free survival. The median durations for non-ALM patients were 28.0 months (mean, 41.3) and 24.0 months (mean, 35.7), respectively. Patients with tumor-positive SLN underwent subsequent complete lymph node dissection.
Statistical analysis
All statistical analyses were performed using the GraphPad Prism statistical software package (version 6; GraphPad Software, San Diego, CA, USA) and the SPSS statistical software package (version 12.0; SPSS, Chicago, IL, USA), as reported previously. 8, 9 Briefly, we used the Kaplan-Meier method to evaluate melanoma-specific survival and disease-free survival, and compared survival curves using the log-rank test. Fisher's exact test, v 2 -test and Mann-Whitney U-test were used to compare the prognostic factors between patients with ALM and those with non-ALM as appropriate. The influences of various factors on survival were also analyzed with the Cox proportional hazards regression model. P < 0.05 was considered to indicate statistical significance.
RESULTS

Patient data
Comprehensive clinical and histopathological data of all 252 patients are shown in Table 1 . There were 106 (42.1%) male and 146 (57.9%) female patients. All patients were Japanese, with a mean age of 60.1 years (range, 2-91). Of the total of 252 melanomas, 121 were ALM at acral sites and 131 were non-ALM (superficial spreading melanoma, n = 66 patients; nodular melanoma, n = 44; lentigo maligna melanoma, n = 21).
Acral lentiginous melanoma more commonly arose in elderly patients than non-ALM (P < 0.0001). Primary tumor size was larger in ALM than in non-ALM (P = 0.005). As for tumor thickness and tumor-node-metastasis (TNM) stage, in situ lesions were more frequently observed in ALM; there was no significant difference in the distribution of tumor thickness or TNM stage between ALM and non-ALM when excluding the in situ lesions (P = 0.80 and 0.68, respectively). Other factors including sex and a delayed diagnosis did not significantly differ between the two groups. We also found no significant difference in melanoma-specific survival or disease-free survival between the patients with ALM and those with non-ALM (P = 0.98 and 0.70, respectively). 
Sentinel lymph node biopsy
We next examined the biological behavior of ALM and non-ALM at regional lymph nodes. Because the American Joint Committee on Cancer recommends SLN biopsy for patients with thick (>1 mm) or ulcerated melanoma, we retrieved 158 patients with such melanomas (63 ALM and 95 non-ALM) and compared them (Table 2) . SLN biopsy was performed on 44 patients (69.8%) with ALM and 76 patients (80.0%) with non-ALM. Among the patients who underwent SLN biopsy, 10 (22.7%) with ALM and 30 (39.5%) with non-ALM had tumorpositive SLN. There was no significant difference in these proportions between ALM and non-ALM. Interestingly, systemic metastasis without preceding lymph node metastasis (direct systemic metastasis via the blood flow) was rarely observed in both patients with ALM (0%) and those with non-ALM (0.8%).
Treatment
The treatment patterns of the patients with ALM and non-ALM are summarized in Table 3 ; almost all patients (ALM, 99.2%; non-ALM, 97.8%) who had melanoma-positive lymph node underwent subsequent lymph node dissection. Patients with non-ALM more frequently underwent such dissection than those with ALM (P = 0.042). Few of the patients received radiation therapy (ALM, 3.3%; non-ALM, 7.6%). Patients who experienced systemic metastasis primarily underwent dacarbazinebased chemotherapy.
Prognostic factors of ALM and non-ALM
Prognostic factors of the patients with ALM and non-ALM are summarized in Table 4 . Because ALM included significantly more in situ lesions than non-ALM and in situ melanoma rarely impairs patient survival, we compared the prognostic factors of the patients with ALM and non-ALM after excluding the patients with in situ melanoma. Among those with ALM, significant adverse prognostic factors were male sex, presence of ulceration of primary tumor, SLN metastasis, large primary tumor, thick primary tumor and advanced TNM stage. Patients who underwent an incisional biopsy did not have a worse prognosis than those who underwent an excisional one. Patients with non-ALM had similar adverse prognostic factors to those with ALM, namely, male sex, presence of ulceration of primary tumor, SLN metastasis, large primary tumor, thick primary tumor and advanced TNM stage. We did not find any remarkable difference in the prognostic factors that affected patient survival between the ALM group and non-ALM group.
Kaplan-Meier survival curves for patients with ALM and non-ALM Kaplan-Meier survival curves are shown in Figures 1 and 2 . Likewise in the comparison of prognostic factors, we excluded the in situ melanoma from survival analyses. There were no significant differences in melanoma-specific survival and disease-free survival between ALM and non-ALM. When we stratified the patients by tumor thickness (T1 + T2 or T3 + T4) and TNM stage, we also failed to identify a significant difference between ALM and non-ALM.
Multivariate analysis
The Cox multivariate analysis of the prognostic factors for patients is shown in Table 5 , inclusive of six variables (age, sex, ALM or not, thickness of the primary tumor, ulcer and TNM stage). There was no significant difference in tumor subtype (ALM vs non-ALM) in the Cox multivariate analysis. Age, sex, tumor thickness, ulcer and TNM stage were significantly correlated with the MSS (Table 5) .
DISCUSSION
Recent emerging molecular-targeted therapies have yielded dramatic improvements in the treatment of melanoma patients and significantly prolonged patient survival. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] However, owing to the rarity of ALM, only limited data are available about Figure 1 . Kaplan-Meier survival curves of the patients with acral lentiginous melanoma (ALM) and non-ALM. (a) Melanoma-specific and (b) disease-free survival of all patients except for those with in situ melanoma. There was no significant difference between ALM and non-ALM in both melanoma-specific survival and disease-free survival. When we stratified the patients by tumor thickness, we found no significant difference in (c) melanoma-specific and (d) disease-free survival between ALM and non-ALM.
this condition and the efficacy of the new therapies for it in terms of actually improving patient outcomes. Against this background, we conducted a retrospective review of our patients, who included a relatively large number of ALM patients, and made several interesting observations. We demonstrated that ALM did not differ from non-ALM in terms of patient survival and prognostic factors. Incisional biopsy can also be allowed for both ALM and non-ALM. The patients in this study were treated in a single hospital where the treatment strategy was relatively consistent and the data suggested that we can consider ALM as being equivalent to non-ALM in a clinical context under our conventional management (complete surgical resection of the primary melanoma with SLN biopsy, followed by node dissection if necessary, with or without dacarbazine-based chemotherapy for systemic metastasis).
When we compare the background data between the patients with ALM and non-ALM, statistically significant differences were observed in tumor thickness, TNM stage, patient age and tumor size. The proportion of in situ lesions (Tis) was significantly higher in ALM than in non-ALM, but when we excluded these lesions, the distributions of tumor thickness (T1, 2, 3 or 4) and TNM stage (I, II, III or IV) were similar between the two groups. Regarding patient age, ALM patients were significantly older than non-ALM patients. Considering that the older age was a significant adverse prognosis factor among ALM patients (but not among non-ALM patients), there Figure 2 . Kaplan-Meier survival curves of the patients with acral lentiginous melanoma (ALM) and non-ALM. When we stratified the patients by tumor-node-metastasis (TNM) stage (I, II, III or IV), we found no significant difference in melanoma-specific survival between ALM and non-ALM. is a possibility that the difference in age could affect the survival in ALM patients. Also, tumor size was significantly larger in ALM than in non-ALM, which is another potential source of bias. This difference in tumor size might have been due to the presence of nodular melanoma (showing vertical invasion without horizontal spread) and lentigo maligna melanoma (arising on the face and thus easily noticeable). Our current data show that patients with ALM tended to have shorter melanoma-specific survival and disease-free survival than those with non-ALM, albeit not significantly, and the difference in size and patient age might have been a reason for this.
Another interesting finding is that ALM is most likely initially to metastasize to the regional lymph nodes and hardly undergoes systemic metastasis directly via the blood flow (non-lymphogenous metastasis). This highlights the importance of SLN biopsy as initial management and physical examination of the lymph nodes during the follow-up period. Furthermore, non-ALM is more likely to affect the SLN than ALM, although the difference did not reach statistical significance (Table 3) . Reflecting this tendency, complete lymph node dissection was more frequently performed on patients with non-ALM. We could not rule out the potential impact of lymph node dissection on patient survival, but suppose that this impact was not substantial because previous studies demonstrated that complete lymph node dissection had little influence on patient survival. 20, 21 In conclusion, our data suggest that ALM and non-ALM are not essentially different in their biological behavior; therefore, for initial treatment, ALM and non-ALM can be handled using the same strategy. Given the infrequency of BRAF mutations in ALM, we speculate that the efficacy of BRAF inhibitors may be less important than immune checkpoint inhibitors, but it is necessary to accumulate more data to elucidate the efficacy of these therapies in ALM patients. We believe that our results will help in achieving this goal as a historical control.
